Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early tripl...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
29 Sep 2019
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenop...
Prof George Sledge - Stanford Health Care, Stanford, USA
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
29 Sep 2019
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postme...
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )
29 Sep 2019
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-po...
Prof George Sledge - Stanford Health Care, Stanford, USA
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Comment: CDK4/6 inhibitors in advanced breast cancer
Prof Nadia Harbeck - University of Munich, Munich, Germany
Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
29 Sep 2019
Immunotherapy added to chemotherapy improves pathological complete response in e...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
Important developments in radiation oncology
Dr Ana Botero - Memorial Healthcare System, Hollywood, FL, USA
Important developments in radiation oncology ( Dr Ana Botero - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA tr...
Dr Connie Guaqueta - Memorial Cancer Institute, Miami, USA
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials ( Dr Connie Guaqueta - Memorial Cancer Institute, Miami, USA )
26 Jul 2019